COMBIHALE-FF 250MG REDICAPS

Description

COMBIHALE-FF 250MG REDICAPS combine Formoterol Fumarate (250 mcg), a long-acting beta-2 agonist (LABA), and Fluticasone Propionate (250 mcg), an inhaled corticosteroid (ICS), in a convenient redicap form for inhalation therapy. This fixed-dose combination provides both bronchodilation and anti-inflammatory effects to control and prevent symptoms of asthma and chronic obstructive pulmonary disease (COPD).

Formoterol works by relaxing airway muscles to improve airflow, while fluticasone reduces inflammation and swelling in the lungs. The REDICAPS are designed for use with a dry powder inhaler, delivering medication directly to the lungs for rapid and effective relief.

Key Benefits:

• Dual-action inhalation therapy for enhanced respiratory control

• Reduces airway inflammation and bronchoconstriction

• Helps prevent asthma attacks and COPD exacerbations

• Fast-dissolving capsule form for easy inhalation

Indications:

• Maintenance treatment of asthma

• Management of chronic obstructive pulmonary disease (COPD)

Dosage:
As prescribed by the physician, typically one capsule inhaled twice daily using a dry powder inhaler.

Precautions:
Not suitable for acute bronchospasm relief. Use under medical supervision. Possible side effects include oral thrush, tremors, and headache.